Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 20:41:e02296.
doi: 10.1016/j.idcr.2025.e02296. eCollection 2025.

A new approach to treat carbapenem resistant Acinetobacter baumannii (CRAB) bacteremia using sulbactam-avibactam combination: A case report

Sameer Alzaidi  1 , Manahil Alharthi  1 , Hams Alshammamri  1 , Yasir Almalki  1 , Osama Almalki  1 , Shahad Alqahtani  1 , Mohammed Alosaimi  1 , Nouran Althumali  1
Affiliations
Case Reports

A new approach to treat carbapenem resistant Acinetobacter baumannii (CRAB) bacteremia using sulbactam-avibactam combination: A case report

Sameer Alzaidi et al. IDCases. .

Abstract

Carbapenem resistant Acinetobacter baumannii (CRAB) infections are serious disease that can be fatal. Only a few therapeutic options are available, with conflicting data for their meaningful clinical outcomes. Here, we report a case of 83-year-old female CRAB bacteremia that was successfully treated with ceftazidime-avibactam and ampicillin-sulbactam combination after failing guidelines directed therapy.

Keywords: Bacteremia; CRAB infections; Novel therapeutic approach.

PubMed Disclaimer

Conflict of interest statement

The authors declare that this case report was not conducted under any commercial or financial relationships.

Figures

Fig. 1
Fig. 1
Clinical improvement depicts by significant improvent in the vital signs.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Jiang Y., Ding Y., Wei Y., Jian C., Liu J., Zeng Z. Carbapenem-resistant Acinetobacter baumannii: a challenge in the intensive care unit. Front Microbiol. 2022;13 - PMC - PubMed
    1. Perez S., Innes G.K., Walters M.S., Mehr J., Arias J., Greeley R., Chew D. Increase in hospital-acquired carbapenem-resistant acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 admissions - New Jersey, February-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(48):1827–1831. Dec 4. - PMC - PubMed
    1. Appaneal H.J., Lopes V.V., LaPlante K.L., Caffrey A.R. Treatment, clinical outcomes, and predictors of mortality among a national cohort of admitted patients with Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2022;66(3) Mar 15. - PMC - PubMed
    1. Tabah A., Buetti N., Staiquly Q., Ruckly S., Akova M., Aslan A.T., Leone M., Conway Morris A., Bassetti M., Arvaniti K., Lipman J., Ferrer R., Qiu H., Paiva J.A., Povoa P., De Bus L., De Waele J., Zand F., Gurjar M., Alsisi A., Abidi K., Bracht H., Hayashi Y., Jeon K., Elhadi M., Barbier F., Timsit J.F., EUROBACT-2 Study Group, ESICM, ESCMID ESGCIP and the OUTCOMEREA Network Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. Intensive Care Med. 2023;49(2):178–190. (Feb) - PMC - PubMed
    1. Spernovasilis N., Ishak A., Tsioutis C., Alon-Ellenbogen D., Agouridis A.P., Mazonakis N. Sulbactam for carbapenem-resistant Acinetobacter baumannii infections: a literature review. JAC Antimicrob Resist. 2025;7(2) (Apr) - PMC - PubMed

Publication types

LinkOut - more resources